此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

脓毒症血液动力学复苏的限制性或自由性液体 (FRESHLY)

脓毒症中的液体限制复苏与低血压荟萃分析(新鲜):ARISE FLUIDS、CLASSIC、CLOVERS 和 EVIS 试验的个体患者数据荟萃分析

A prospective, individual patient data meta-analysis (IPDMA) of four multicentre, open-label, randomised clinical trials of initial haemodynamic resuscitation in patients with septic shock.

研究概览

详细说明

This study is a prospective, individual patient data meta-analysis (IPDMA) of four multicentre, open-label, randomised clinical trials of initial haemodynamic resuscitation in patients with septic shock.

The investigators will include four multicentre, open-label, randomised, clinical trials:

  • Australasian Resuscitation in Sepsis Evaluation Fluids of Vasopressors in Emergency Department Sepsis (ARISE FLUIDS) trial conducted in Australia and New Zealand. ClinicalTrials.gov identifier NCT04569942
  • Conservative versus Liberal Approach to fluid therapy of Septic Shock in intensive Care (CLASSIC) trial conducted in seven European countries. ClinicalTrials.gov identifier NCT03668236
  • Crystalloid Liberal or Vasopressors Early (CLOVERS) trial conducted in the United States. ClinicalTrials.gov identifier NCT03434028
  • Early Vasopressors in Sepsis (EVIS) trial conducted in the United Kingdom. ClinicalTrials.gov identifier NCT05179499

All four trials have all received relevant approval from a research ethics committee with a locally appropriate method of obtaining consent. These trials are prospectively chosen prior to the results of any individual trial being known because they are investigating the same broad question in patients with acute septic shock across several countries. The investigators of these trials collaborated to harmonise data and outcomes as far as possible across all trials to facilitate an IPDMA.

The aims to provide high level evidence to address the question of whether a fluid sparing/early vasopressor approach or a liberal fluid/later vasopressor approach to initial haemodynamic resuscitation in septic shock results in improved outcomes, including mortality.

研究类型

观察性的

注册 (估计的)

7838

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

All trials include adult patients requiring resuscitation for hypotension or hypoperfusion due to suspected sepsis as defined in the original studies. Participants may be enrolled in the emergency department, acute care ward or intensive care unit.

描述

Inclusion Criteria:

Participants of the ARISE FLUIDS, CLASSIC, CLOVERS & EVIS trials who had:

  • Suspected or proven infection
  • Systolic blood pressure (SBP) <100 mm Hg OR mean arterial pressure (MAP) <65 mm Hg
  • Lactate ≥ 2.0 mmol/L
  • Requirement for vasopressors to meet perfusion targets

Exclusion criteria:

Participants not in the ARISE FLUIDS, CLASSIC, CLOVERS & EVIS trials

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:OTHER
  • 时间观点:OTHER

队列和干预

团体/队列
干预/治疗
Vasopressors

A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets

A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets

Fluids

A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.

A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
All-cause mortality at 90 days post randomisation
大体时间:90 days

Death from any cause at 90 days after randomisation

90 days

次要结果测量

结果测量
措施说明
大体时间
Time from randomisation to death
大体时间:Up to day 90

Time from randomisation to death

Up to day 90
Incidence of mechanical ventilation
大体时间:from randomisation until day 90 post-randomisation

Commencement of mechanical ventilation from randomisation until day 90 post-randomisation

from randomisation until day 90 post-randomisation
Incidence of acute renal replacement therapy
大体时间:from randomisation until day 90 post-randomisation

Commencement of renal replacement therapy from randomisation until day 90 post-randomisation

from randomisation until day 90 post-randomisation
Days alive free of organ support at 28 days post randomisation
大体时间:from randomisation until day 28 post-randomisation

days the patient is alive and receiving nil organ support from from randomisation until day 28 post-randomisation

from randomisation until day 28 post-randomisation
Duration of hospital stay
大体时间:From randomisation until day 90 post-randomisation

Length of time in hospital from randomisation until death or hospital discharge or day 90 post-randomisation

From randomisation until day 90 post-randomisation
Incidence of serious adverse events
大体时间:from randomisation until day 90 post-randomisation

Number of adverse events from randomisation until day 90 post-randomisation

from randomisation until day 90 post-randomisation
Duration of intensive care unit (ICU) stay
大体时间:From randomisation until day 90 post-randomisation

Length of time in ICU from randomisation until death or hospital discharge or day 90 post-randomisation

From randomisation until day 90 post-randomisation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年11月1日

初级完成 (估计的)

2028年11月1日

研究完成 (估计的)

2028年11月1日

研究注册日期

首次提交

2022年6月3日

首先提交符合 QC 标准的

2022年7月7日

首次发布 (实际的)

2022年7月12日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅